“…So far, there are several proteomic and biochemical multi-step technologies used for discovery and validation of biomarkers, such as SELDI-ToF MS, LC-MS/MS, 1D PAGE, and Western blot. For the current research, SELDI-ToF MS was preferred because it is an effective array technology, allowing complex analysis of biological materials and providing a rapid protein expression profile useful for biomarker identification [ 21 , 22 ]. Furthermore, SELDI-ToF MS technology has been successfully applied in biomarker discovery for a number of cancer types, such as acute myeloid leukemia [ 23 , 24 ], pancreatic cancer [ 25 ], lung cancer [ 26 , 27 ], ovarian cancer [ 28 ] and gastric adenocarcinoma [ 29 ], but insufficiently reported in glioblastoma [ 30 ].…”